Clinical Trial Update: Persantin Preceding Elective PCI [Phase 4]

View source ↗

Summary

Phase 4 trial assessing Persantin (dipyridamole) administered before elective Percutaneous Transluminal Coronary Angioplasty has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Coronary Heart Disease

Drugs mentioned

• Persantin (dipyridamole)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Coronary Heart Disease, Percutaneous Transluminal Coronary Angioplasty | Phase 4 | Status: COMPLETED